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Vascular access site thrombosis is a major cause of morbidity in patients receiving hemodialysis. The role of hypercoag-
ulable states in recurrent vascular access site thrombosis remains poorly understood. Data are limited regarding systemic
anticoagulation to improve access graft patency, because of concern about hemorrhagic complications. We determined the
prevalence of hypercoagulable states and clinical outcome (thrombotic and hemorrhagic) after initiation of antithrom-
botic therapy in a series of patients with recurrent vascular access site thrombosis. We evaluated 31 patients who had
sustained 119 thrombotic events that resulted in vascular access graft failure during the year before evaluation.
Sixty-eight percent of patients tested had elevated concentrations of antibody to anticardiolipin or topical bovine
thrombin, and 18% of patients tested had heparin-induced antibodies. More than 90% of patients had elevated factor VIII
concentration, 62% had elevated fibrinogen concentrations, and 42% had elevated C-reactive protein concentrations.
Twenty-nine patients were given antithrombotic therapy: 13 with warfarin sodium, 12 with unfractionated heparin
(UFH), and 11 with low molecular weight heparin (LMWH). Seven patients received more than one antithrombotic
agent, sequentially. Nineteen patients have had no thrombotic events since beginning antithrombotic therapy (10 with
warfarin, 3 with UFH, 6 with LMWH). Mean follow-up was 8.6 months (median, 7 months). Eight patients sustained
10 bleeding complications (5 with warfarin, 3 with UFH, and 2 with LMWH). In conclusion, hypercoagulable states are
common in patients with recurrent vascular access site thrombosis. Antithrombotic therapy may increase vascular access
graft patency, but is associated with significant risk for hemorrhage. Prospective studies are needed to evaluate the role
and safety of antithrombotic agents in improving vascular access graft patency. (J Vasc Surg 2003;38:541-8.)
End-stage renal disease (ESRD) is a significant and
growing medical problem in the United States. On Decem-
ber 31, 1999, the point prevalence of patients with ESRD
patients receiving hemodialysis was 209,637, and this num-
ber increased by approximately 4.2% per year between
1995 and 1999.1 Vascular access complications account for
at least 15% of hospitalizations in this population.2 Medi-
care expenditures for vascular access-related procedures
have been estimated at greater than $1 billion per year.3,4
Several large trials have identified thrombosis and fail-
ure to resolve a thrombotic episode as the principal cause of
access site morbidity, representing 80% to 85% of all com-
plications and failures.5-10 The underlying pathologic state
is usually stenosis at the venous end of the graft.11,12
Histologic evaluation of these venous stenoses reveals en-
dothelial and fibromuscular hyperplasia, with subsequent
thrombosis as the cause of outflow stenosis.9,13 In addition,
various reports have noted a significant amount of sponta-
neous vascular access site thrombosis without obvious an-
atomic cause.7,14,15 In the case of early failure, ie, a graft
that never functioned, the likelihood of finding no evidence
of a stenotic lesion is greater. In these cases, other causes,
eg, hypercoagulable states, may be responsible for recurrent
graft thrombosis.
Placement of a polytetrafluoroethylene (PTFE) graft
rather than a native arteriovenous fistula is a clear risk factor
for vascular access failure.9,13 The high failure rate for
PTFE grafts has led to development of bovine mesenteric
vein grafts (Procol; Hancock Jaffe Laboratories, Irvine,
Calif), which in preliminary studies have demonstrated
improved patency rates over those with PTFE grafts.16
Other risk factors that have been suggested in access site
thrombosis include diabetes,17 hypoalbuminemia,18 eryth-
ropoietin therapy,19 and advanced age.17 Occasional stud-
ies have investigated hypercoagulability as a cause of throm-
bosis in vascular access grafts. In general, these studies have
produced inconclusive results, but several have correlated
the presence of antibodies, eg, antiphospholipid anti-
body,20-24 antibody to endothelial cells,25 and anti-bovine
thrombin antibody,26 with increased risk for thrombotic
complications. In addition, inflammatory and procoagulant
host responses to infection are closely related, which sug-
gests that chronic inflammation may lead to a hypercoagu-
lable state.27,28
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Therapeutic options for ESRD and recurrent vascular
access thrombosis can quickly become limited. Whereas
prospective monitoring of access flow and venous dialysis
pressure, combined with prospective angioplasty, improve
vascular access graft survival, this may not be sufficient in
patients with an underlying inflammatory process or hyper-
coagulable state.29-31 Data are limited regarding systemic
anticoagulation to improve access graft patency.14,32 In this
case series, we estimated the prevalence of hypercoagulable
states in a subset of hemodialysis-dependent patients with a
history particularly significant for recurrent vascular access
graft thrombosis. The effect of various antithrombotic
strategies on vascular access graft survival and incidence of
hemorrhagic complications was assessed.
METHODS
Patients. The series included 31 consecutive patients
with dialysis-dependent ESRD and a history of recurrent
vascular access graft thrombosis who were referred to the
Thrombosis Clinic for evaluation for a possible hypercoag-
ulable state between March 2000 and July 2001. Medical
records were reviewed retrospectively for all patients from
the initiation of hemodialysis. Clinical data, ie, cause of
renal failure, duration of hemodialysis, number of vascular
access graft placements since initiation of hemodialysis,
type of graft placed, and thrombotic complications were
recorded for each patient. All patients gave written in-
formed consent for chart review and for blood samples to
be drawn and stored for screening for hypercoagulable
state.
Laboratory studies. At referral to the Thrombosis
Clinic, each patient was evaluated for certain hypercoagu-
lable states. Lupus anticoagulants were detected with a
panel of tests including dilute Russell viper venom screen-
ing and confirmation (American Diagnostica, Greenwich,
Conn).33 Immunoglobulin (Ig) G, IgM, and IgA anticar-
diolipin antibodies were measured with an enzyme-linked
immunosorbent assay (ELISA) as described.34 Specimens
were regarded as positive for antiphospholipid antibodies
when a lupus anticoagulant or anticardiolipin antibody, or
both, were detected. Antibody to topical bovine thrombin
was detected with ELISA, as described.26
Anti-platelet factor 4/heparin (PF4/heparin) antibody
was detected with ELISA, as described.35 In addition,
heparin-induced platelet aggregation assays were per-
formed to test for heparin-dependent antibody. This assay
was performed as described,36 but a difference of 15%,
rather than 25%, or greater in light transmission between
control buffer and one or more heparin-containing samples
was indicative of positive heparin-induced platelet
aggregation.
Plasma fibrinogen was assayed with the method of
Clauss.37 Factor VIII assays were performed with factor
VIII–deficient plasma on a coagulation analyzer (MDA-
180; BioMe´rieux, Durham, NC). C-reactive protein (CRP)
levels were measured with ELISA according to the manu-
facturer’s instructions (DiaMed Eurogen, Cressier sur
Morat, Switzerland). Antithrombin III activity was mea-
sured with a chromogenic assay on the coagulation ana-
lyzer. All assays were performed with plasma drawn at
referral to the clinic. Polymerase chain reaction (PCR)
analysis was performed to identify the thermolabile meth-
lylenetetrahydrafolate reductase (MTHFR) polymorphism,
the 3'-untranslated prothrombin gene polymorphism, and
factor V Leiden, as described.38
Antithrombotic strategies. In 29 patients antithrom-
botic therapy was started at the time of the new access
placement, with either a prophylactic dose of subcutaneous
unfractionated heparin (UFH), a prophylactic dose of the
subcutaneous low molecular weight heparin (LMWH)
enoxaparin (Lovenox), or warfarin sodium (Coumadin),
with a target international normalized ratio (INR) of 2.0 to
3.0. The choice of anticoagulant therapy was not random-
ized but individually selected on the basis of cost, ability to
monitor therapy, and patient ability and willingness to
administer subcutaneous injections. Patients receiving
LMWH therapy were monitored for evidence of accumu-
lation with anti-factor Xa concentration. After initiation of
antithrombotic therapy, episodes of recurrent vascular ac-
cess failure and hemorrhagic complications during antico-
agulant therapy were recorded. Vascular access failure was
defined as loss of bruit or thrill and lack of flow when
cannulated, requiring either placement of a new access graft
or an interventional procedure to reestablish flow.
RESULTS
Demographic characteristics for the 31 patients are
listed in Table I. During the 1 year before evaluation, these
31 patients had 119 thrombotic events (mean, 3.7 events
per patient; range, 1-8 events) that necessitated either an
interventional procedure or placement of a new vascular
access device. Eighty-two events were PTFE graft failures,
32 were primary fistula failures, and 5 were Procol bovine
vein graft failures. Of note, 81 (68%) grafts or fistulas failed
Table I. Patient demographics
n (%)
Age (y)
Mean 44.19  13.6
Range 21-79
Female 24 (77)
African American 28 (90)
Renal diseace
Diabetes 12 (38)
Hypertension 9 (29)
SLE 4 (13)
HIV nephropathy 2 (6)
Other 4 (13)
Previous vascular access failures* 119
Mean per patient 3.7
Range 1-8
Time receiving dialysis (mo)
Median 11.3
Range 2-72
HIV, Human immunodeficiency virus; SLE, systemic lupus erythematosus.
*Number of vascular access failures in the 1 year before evaluation.
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before they could be accessed for hemodialysis. Two pa-
tients also required more than 15 tunneled cuffed catheter
placements each over a 12-month period, because of
thrombotic complications. None of the study patients had
a previous graft that functioned for more than 7 months
(mean period between graft placement and failure, 2.4
months), and eight patients had never had a functioning
graft.
Six patients sustained other thromboembolic complica-
tions. In two patients renal artery thrombosis developed
after renal transplantation surgery, resulting in loss of the
transplanted kidney in both cases. In two patients extensive
venous thrombosis developed after tunneled cuffed cathe-
ters extended into noncannulated veins. Two patients had a
history of spontaneous deep venous thrombosis or pulmo-
nary embolism unrelated to central catheter placement for
dialysis access.
Hypercoagulable state screening. There was a high
incidence of antibodies associated with thrombosis. Eigh-
teen patients (58%) had elevated concentrations of anti-
body to cardiolipin (Fig 1). Four of 29 patients tested also
had lupus anticoagulants. Ten patients had elevated con-
centrations of antibody to topical bovine thrombin (32%)
(Fig 1). Eight patients had elevated concentrations of anti-
body to both cardiolipin and topical bovine thrombin.
Five of 27 patients tested (18%) had heparin-induced
antibodies. In two patients hypercoagulable state was diag-
nosed with PF4/heparin ELISA alone. Neither patient had
thrombocytopenia when tested, although in one patient 15
tunneled cuffed catheters, 1 PTFE graft, and 1 Procol graft
had become occluded in the previous 12 months. In an
additional three patients assay results were positive for
heparin-induced platelet aggregation. Each of these pa-
tients had thrombocytopenia, with a clinical course that
suggested heparin-induced thrombocytopenia and
thrombosis.
Three patients, two of whom were infected with
human immunodeficiency virus, had functional anti-
thrombin III deficiency (41%, 44%, and 51%, respec-
tively; normal range, 72%-132%). Twenty-seven of 29
patients tested (93%) had elevated factor VIII concen-
trations (mean, 278%; range, 196%-502%; Fig 2, A). In
addition, 17 of 27 patients tested (63%) had elevated
concentrations of fibrinogen (mean, 544 mg/dL; range,
455-732 mg/dL; Fig 2, B). Thirteen patients (41.9%)
also had elevated CRP levels (Fig 2, C), which suggested
that more than half of patients with high factor VIII
levels had intrinsically elevated results.
Twenty-five patients (80.6%) had elevated homocys-
teine concentrations (mean, 32.5 mol/L; upper limit of
normal, 13 mol/L). Six of these 25 patients were given
folic acid (dose range, 1-5 mg/d), with documented reduc-
tion in homocysteine concentration to within normal range
in 4 patients. In three patients the thermolabile MTHFR
Fig 1. Concentrations of anticardiolipin antibody (A) and anti-bovine thrombin antibody (B) in 29 study patients.
Broken lines indicate upper limit of normal.
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polymorphism was detected; one patient was homozygous
and two patients were heterozygous for the polymorphism.
One patient was heterozygous for the 3'-untranslated pro-
thrombin gene polymorphism. No patients had factor V
Leiden.
All patients had at least one risk factor for increased
tendency for thrombosis, and 25 of 31 patients had two or
more risk factors.
Antithrombotic therapy. In 29 of 31 patients anti-
thrombotic therapy was started at the next access placement
after being seen in the Thrombosis Clinic. Thirteen patients
received warfarin sodium, 12 received UFH, and 11 re-
ceived LMWH (enoxaparin, 30 mg/d for patients who
weighed 70 kg; 40 mg/d for patients who weighed 70
kg). In all patients who received LMWH, anti-factor Xa
levels were measured within 5 days of initiation of treat-
ment. Seven patients received more than one antithrom-
botic agent, sequentially.
In addition, six patients continued to take previously
prescribed antiplatelet therapy after antithrombotic therapy
was started (five patients, aspirin 325 mg/d; 1 patient,
ticlopidine 250 mg twice daily). In one patient antithrom-
botic therapy was considered too risky because of patient
noncompliance. Another patient has not yet had a new
access graft placed since initial evaluation, and dialysis con-
tinues to be administered with a tunneled cuffed catheter,
without problem. Of the 29 patients given antithrombotic
therapy, 3 had an arteriovenous fistula, 11 had a PTFE
graft, and 15 had a Procol graft. Mean duration of fol-
low-up was 8.6 months (median, 7 months; range, 1-16
months).
Nineteen patients, including the three with an arterio-
venous fistula, have had no thrombotic complications and
continue to have patent functioning grafts (Table II). Ten
of these patients were given warfarin sodium (goal INR, 2.0
to 3.0), 3 were given UFH (mean dose, 6000 U subcuta-
neously every 12 hours), and 6 were given LMWH. Mean
follow-up in these 19 patients was 8.2 months (range, 1-14
months).
Ten patients have sustained 23 recurrent arteriovenous
graft failures during antithrombotic therapy (Table III). Six
of these 10 patients underwent fistulography to identify any
stenosis that may have led to graft failure. In four of these
cases stenotic lesions were identified, and subsequently
were reopened at angioplasty. In the four patients who did
not undergo fistulography, graft failure occurred soon after
placement, and simple thrombectomy was performed. Me-
dian time to first recurrence was 52 days (range, 13-330
days). At the time of graft failure, 2 patients were receiving
warfarin (INR, 1.9 and 2.6, respectively), 3 were receiving
UFH (mean dose, 6000 U every 12 hours), and 5 were
receiving LMWH (enoxaparin, 30 or 40 mg subcutane-
ously once daily). Seven of these patients received repeat
antithrombotic therapy after creation of a new vascular
access site. However, six of these grafts subsequently failed.
Overall, there was no obvious association between choice
of antithrombotic agent and access graft patency.
Eight patients sustained 10 hemorrhagic complications
(Table IV). Six bleeding complications were perigraft he-
matomas (4, Procol graft; 2, PTFE graft), which resulted in
loss of two grafts. One patient required transfusion with
packed red blood cells because of a significant decrease in
hematocrit after development of a thigh hematoma. Five
bleeding complications occurred in patients receiving war-
farin therapy, with INR values at the time of hemorrhage
ranging from 1.3 to 9.2 (Table 4). None of these patients
were receiving an antiplatelet agent. Bleeding complica-
tions developed in three patients receiving UFH (6000,
7000, and 7500 units subcutaneously every 12 hours,
respectively). One patient in whom a graft-related hema-
toma developed was taking aspirin, and the patient with a
thigh hematoma was taking ticlopidine in addition to hep-
arin therapy. Bleeding complications in the two patients
receiving LMWH occurred in the setting of inadvertent
Fig 2. Concentrations of factor VIII (A), fibrinogen (B), and C-reactive protein (C) in 29 study patients. Broken lines
indicate upper limit of normal.
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high doses of enoxaparin (60 mg and 30 mg, respectively,
every 12 hours). Neither of these patients was taking anti-
platelet agents.
Management of heparin-induced thrombocyto-
penia Heparin-induced antibodies were detected in 5 of
27 patients (18%) tested. Two of these patients had sys-
temic lupus erythematosus and subsequently died, one
suddenly, presumed due to cardiac arrhythmia, and one
due to sepsis. Two patients were given warfarin therapy and
have had no further heparin with dialysis. Both have func-
tional vascular access grafts, at 9 and 13 months, respec-
tively, since beginning warfarin therapy. In the fifth patient
results of PF4/heparin ELISA were positive and heparin-
induced platelet aggregation assay was negative. This pa-
tient was not given anticoagulant therapy, mainly because
of noncompliance issues, but has continued to receive
heparin during hemodialysis. Platelet count remains stable,
and the patient has no history of thrombosis other than
related to venous access. However, recurrent access throm-
bosis continues, and two arteriovenous grafts have failed
since initial evaluation. No problems with tunneled cuffed
catheter thrombosis have occurred, however.
DISCUSSION
The role of hypercoagulable risk factors in recurrent
vascular access failure, particularly primary failure, ie, access
failure within 30 days of placement, remains undetermined.
In this series we found a high prevalence of antiphospho-
lipid antibodies in patients with a history of frequent epi-
sodes of vascular access thrombosis. Previous studies have
reported wide variation in prevalence of elevated IgG anti-
cardiolipin antibody concentration in patients receiving
hemodialysis.20-24 A cross-sectional study by Prakash et
al23 found a significant prevalence of these antibodies in
patients with arteriovenous grafts (22%) compared with
patients with native fistulas (6%). This increased prevalence
was associated with increased odds of having had recurrent
arteriovenous graft thrombosis. A prospective study by
Valeri et al24 confirmed that increased anticardiolipin anti-
bodies were correlated with decreased arteriovenous graft
survival in patients receiving hemodialysis.
We also found elevated antibody levels to topical bo-
vine thrombin preparation. During vascular surgery proce-
dures, patients are often exposed to bovine thrombin,39
and patients exposed to this xenogeneic hemostatic agent
frequently develop anti-bovine thrombin antibodies.40 An-
ti-bovine thrombin antibodies may result in a hypercoagu-
lable state by several mechanisms, including interference
with neutralization of thrombin by antithrombin III41 and
interference with the activation of protein C.42 Patients
with PTFE grafts and elevated antibody levels to topical
bovine thrombin have significantly more problems with
access thrombosis.26 In addition, antiphospholipid anti-
bodies may develop in patients exposed to topical bovine
thrombin preparations, which may contribute to risk for
thrombosis.43,44 In our opinion, topical hemostatic agents,
and in particular topical bovine thrombin, should be used
with caution, because the risk for subsequent thromboem-
bolic complications remains unclear.
In this highly selected population with recurrent access
thrombosis, we found a relatively high prevalence of hepa-
rin-induced antibodies. This degree of prevalence has not
previously been reported in dialysis-dependent patients in
general, but no studies have specifically investigated the
subset of patients with recurrent vascular access fail-
ure.35,45-50 In two patients with heparin-induced antibod-
ies, there was dramatic improvement in access patency after
discontinuing heparin with hemodialysis and beginning
treatment with warfarin, which suggests that these antibod-
ies may have a role in recurrent vascular access occlusion in
some patients.
Most patients in this series had elevated factor VIII
concentrations (93.5%) or elevated fibrinogen concentra-
tions (63%). High factor VIII concentration is an indepen-
dent risk factor for thrombosis, with greater risk for venous
thrombosis than for arterial thrombosis.51 Sustained in-
creased factor VIII levels have previously been reported in
hemodialysis-dependent patients, but no prospective stud-
Table II. Patients without recurrent thrombotic events
(n  19)
Access type Warfarin UFH LMWH
AV fistula (n  3) 2 0 1
PTFE graft (n  6) 4 1 1
Procol graft (n  10) 4 2 4
UFH, Unfractionated heparin; LMWH, low molecular weight heparin; AV,
arteriovenous; PTFE, polytetraflouroethylene.
Table III. Patients with recurrent thrombotic events
(n  10)
Access type Warfarin UFH LMWH
PTFE graft (n  65) 1 (INR, 1.9) 1 4
Procol graft (n  45) 1 (INR, 2.6) 2 1
UFH, Unfractionated heparin; LMWH, low molecular weight heparin;
PTFE, polytetraflouroethylene; INR, international normalized ratio.
Table IV. Hemorrhagic complications of anticoagulation
therapy
Anticoagulant No. of Patients Complication
Warfarin (INR 1.3, 2.1,
5.4, 9.2)
5 4 Graft hematomas
(INR 5.3) 1 Rectal bleeding
UFH (6000 U q12h, 7500
U q12h)
3 2 Graft hematomas
(7000 U q12h) 1 Thigh hematoma
LMWH (enoxaparin,
60 mg q12h)
2 1 Thigh hematoma
(enoxaparin 30 mg q12) 1 Hemoperitoneum
INR, International normalized ratio; UFH, unfractionated heparin;
LMWH, low molecular weight heparin.
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ies have correlated elevated levels of factor VIII with vas-
cular access failure.52,53
Plasma fibrinogen also is an independent risk factor for
venous thrombosis and for development of cardiovascular
disease in patients with chronic renal failure.54,55 Song et
al56 prospectively evaluated the association of plasma fi-
brinogen concentration and vascular access failure in a
cohort of 102 patients undergoing long-term hemodialysis
and found that cumulative vascular access survival was
significantly lower in patients with high plasma fibrinogen
levels (460 mg/dL) compared with patients with normal
levels (460 mg/dL). A smaller study by De Marchi et al57
evaluated vascular access thrombosis in patients with a
native fistula, and fibrinogen was not found to be a risk
factor for fistula failure.
The association between inflammatory disorders and
vascular access thrombosis is poorly defined. While we have
not found any studies showing an association between
elevated CRP levels and vascular access thrombosis, inflam-
matory and procoagulant host responses are closely relat-
ed.27 Jurado et al28 reported a series of patients in whom
vascular access thrombosis occurred in close temporal asso-
ciation with infectious or inflammatory processes. CRP
levels were not reported in this study, but in our series more
than 40% of patients had elevated CRP levels. Patients with
a history of recurrent vascular access failure and ongoing
inflammation may be candidates for short-term anticoagu-
lation therapy, eg, 1 to 3 months after access graft place-
ment or until the inflammatory stimulus has resolved.
The results of this preliminary study suggest that use of
antithrombotic agents may be associated with increased
vascular access graft patency in certain patients. However,
use of antithrombotic agents in patients with ESRD is
associated with concomitant risk for hemorrhagic compli-
cations.14,58,59 Relatively few studies have investigated use
of antithrombotic therapy to improve access graft patency.
Two small studies of anticoagulation with warfarin have
reported significant hemorrhagic complications, with no
clear evidence of improved access graft survival.14,32 LeSar
et al14 used warfarin (goal INR, 2.0-3.0) in 10 patients with
PTFE grafts and associated hypercoagulable states. These
10 patients had 23 PTFE graft thromboses despite warfarin
therapy. In addition, there were four separate hemorrhagic
complications in three patients, and two false aneurysms
that required operative repair. A randomized controlled
trial32 of warfarin therapy (target INR, 1.5-2.0) or placebo
in hemodialysis-dependent patients with newly placed
PTFE grafts was terminated early because of excess bleed-
ing complications coupled with the failure of warfarin to
prolong graft survival. We found that of 13 patients given
warfarin, 8 had functional access grafts at mean follow-up
of 8.6 months, although 5 patients did sustain hemorrhagic
complications.
No published studies have evaluated a possible role for
heparin in improving access graft survival. Heparin, an
inhibitor of smooth muscle cell migration and prolifera-
tion, reduces intimal hyperplasia after vascular access graft
implantation and vascular injury.60,61 Subcutaneous ad-
ministration of LMWH also reduced the incidence of inti-
mal hyperplasia in an animal model.62 As a result, heparin
may have additional benefits over and above its anticoagu-
lant properties in management of vascular access graft
failure in patients with ESRD. However, surprisingly little
is known about the risk for hemorrhagic complications with
heparin therapy in patients with ESRD.63,64
LMWH has several potential benefits over UFH,58 but,
because LMWH is cleared through the kidneys, the safe
dosage for use in this population is unclear. Few studies of
the pharmacokinetics of LMWH in patients with ESRD
have been done, and the results are conflicting.65-67 In
addition, there are no published studies of multiple-dose
LMWH pharmacokinetics that evaluated possible accumu-
lation of anticoagulant activity in patients with severe renal
impairment. There are, however, reports of hemorrhagic
complications associated with use of LMWH in patients
with ESRD, especially if aspirin is used concomitantly.59,68
In this series, a low dose of LMWH, either 30 or 40 mg of
enoxaparin once daily, was chosen in an attempt to increase
vascular access graft patency. There were no bleeding com-
plications at this dose, and 6 of 11 patients treated with this
regimen have had no recurrent thrombotic events at mean
follow-up of 8.2 months (median, 7 months).
In conclusion, hypercoagulable states may contribute
to vascular access graft thrombosis, particularly in patients
with a history of multiple, and early, access site thrombosis.
We found a high incidence of antibodies associated with
thrombosis, as well as elevated factor VIII and fibrinogen
concentrations, in patients with recurrent vascular access
thrombosis. These preliminary results suggest that anti-
thrombotic therapy in certain patients may decrease the
incidence of vascular access site failure. Results with
LMWH and warfarin seem promising. However, use of
antithrombotic therapy, and in particular warfarin sodium,
in patients with ESRD was associated in our series with
increased risk for hemorrhagic complications. Further pro-
spective controlled studies, including pharmacokinetic
studies of LMWH and UFH in hemodialysis-dependent
patients, are needed to evaluate the optimal antithrombotic
agent and safe dosage in patients with ESRD.
We thank Keith Klemp, Mary Pound, and Zuowei Su,
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anti-bovine thrombin antibody ELISA.
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